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Background and purpose of the study: Acenaphtho derivatives have been reported as antitumor agents. Due to
this fact and also with the aim of developing the chemistry of potentially bioactive heterocyclic compounds via efficient
reactions, a facile procedure for the synthesis of 9-(alkylthio)-acenaphtho[1,2-e]-1,2,4-triazines via two step condensation
of thiosemicarbazide and acenaphtylene-9,10-quinone to form acenaphtho[1,2-e]-1,2,4-triazine-9(8H)-thiones and
subsequent reaction with benzyl chloride derivatives is reported.
Methods: 9-(alkylthio) acenaphtho[1,2-e]-1,2,4-triazines were synthesized via the reaction of acenaphtho-9,10-quinone
with thiosemicarbazide, and then with the benzyl chloride derivatives. Cytotoxicity of some prepared compounds was
assessed through MTT assay on three different human cancerous cell lines (HL-60, MCF7, and MOLT-4 cells). Molecular
docking studies were performed via AutoDock4.2 software in order to confirm an apoptosis-inducing activity of
acenaphtho scaffolds via the Bcl-2 protein.
Results: Excellent yields of the products, short reaction times and simple work-up are attractive features of this
synthetic protocol. The evaluated compounds exhibited moderate to good cytotoxic activities. Docking results
on the active site of B-cell lymphoma 2 (Bcl-2) supported the experimental biological data and agreed well with
previous in silico data for commonly used anti-cancer drugs. Moreover; results were analyzed considering binding
efficiency indices.
Conclusions: The outcomes of the present study may be helpful in future targeting of Bcl-2 with the aim of
developing apoptosis-inducing agents.
Keywords: Synthesis, Acenaphtho-9,10-quinone, Cytotoxic activity, DockingIntroduction
Economic generation of bioactive compounds has been
a major concern in modern organic chemistry [1]. In this
regard, development of novel compounds and especially
diverse small molecule scaffolds caused higher attention
of medicinal and biological chemists [2-4]. This can be
attributed to the growing requirement in assembling* Correspondence: mirir@sums.ac.ir
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distribution, and reproduction in any mediumlibraries of structurally complex substances to be evalu-
ated as hit/lead compounds in drug discovery projects.
Polycyclic aromatic hydrocarbon (PAH) heterocycles are
highly important structural units in a variety of pharmaco-
logically active substances [5-9]. At first glance, rigid poly-
cyclic structures seem to have role in the development of
antitumor agents owing to their ability in insertion be-
tween stacked base pairs of oligonucleotides and action as
intercalator [10-12]. Particularly important is that when
these planar polycyclic heterocycles bear appropriate side
chains, further interactions with other important macro-
molecules might be envisaged [11,13].entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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been constructed around the acenaphtho core [14,15].
Some of the acenaphtho derivatives containing thiazole
backbone have been reported as antitumor agents [16].
Recently in an attempt to develop protein-targeted
instead of DNA-targeted antitumor agents, some deriv-
atives of 8H-acenaphtho[1,2-b]pyrrole have been con-
structed [17].
The authors demonstrated that 8-oxo-3-thiomorpholin-
4-yl-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile could
serve as an apoptosis-inducing agent via interacting
Bcl-2 protein [17]. It is well known that the Bcl-2
family of proteins is comprised of pro-apoptotic and
anti-apoptotic proteins and all members of this fam-
ily are not anti-apoptotic. Anti-apoptotic Bcl-2 family pro-
teins, including Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1,
prevent cell death by binding and sequestering pro-
apoptotic proteins so, inhibition of these anti-apoptotic
proteins might be lethal to cancer cells.
Indeed, Bcl-2 proteins have been regarded as import-
ant targets for anti-neoplastic drug development and
Bcl-2 gen has been identified as over expressed in vari-
ous cancers. Bcl-2 is an anti-apoptotic protein possessing
an important role in various types of cancers. Bcl-2 is
the member of the Bcl-2 family of apoptosis regulator
proteins which is encoded by the BCL2 gene [18,19].
Various reactions of acenaphthaquinone with nucleo-
philes, organic and inorganic reagents have been reviewed
elsewhere [20,21]. In the framework of our program to de-
velop the chemistry of potentially bioactive heterocyclic
compounds [22] and in connection with our ongoing
interests in this field [23-25], we represent here a facile
procedure for the synthesis of 9-(alkylthio)-acenaphtho
[1,2-e]-1,2,4-triazines via two step condensation of thiose-
micarbazide and acenaphtylene-9,10-quinone to form ace-
naphtho[1,2-e]-1,2,4-triazine-9(8H)-thiones and subsequent
reaction with benzyl chloride derivatives. Prepared com-
pounds were subjected to cytotoxic assay in three differ-
ent cancerous cell lines. Moreover; molecular docking
was used to gain further insight into the binding mode
and binding affinity of acenaphtho derivatives in the
active site of Bcl-2.
Material and methods
All of the reagents were purchased from commercial
sources and were freshly used after being purified by
standard procedures. Melting points were determined
on the Electro-thermal Melting Point apparatus and
were uncorrected. Infrared spectra were recorded on the
Shimadzu-420 infrared spectrophotometer. 1H-NMR
and13C-NMR spectra were recorded in DMSO-d6 or
CDCl3 on Brucker 300 MHz spectrometer (Chemical
shifts are given in parts per million or ppm). Mass spectra
were recorded on a MS model 5973 Network apparatus ationization potential of 70 eV. Elemental analyses (C, H, N)
were performed by the Microanalytical Unit.
General procedure for preparation of acenaphtho
[1,2-e]-1,2,4-triazine-9(8H)-thione (3)
To the acenaphtylene-9,10-quinone (5 mmol) and thiosemi-
carbazide (5 mmol) in chloroform (30 mL), small amount of
acetic acid was added as an catalyst. The reaction mix-
ture was stirred under reflux condition. The progress
of the reaction was monitored with TLC and at the
completion of the reaction, The precipitated product
was filtered off, washed with mixture of H2O/EtOH, dried
and recrystallized from ethanol to give yellow crystalline
acenaphtho[1,2-e]-1,2,4-triazine-9(8H)-thione (Scheme 1).
General procedure for preparation of 9-(alkylthio)-acenaphtho
[1,2-e]-1,2,4-triazines (5a-g)
To a well-stirred solution of acenaphtho[1,2-e]-1,2,4-tria-
zine-9(8H)-thione (3) in 10 ml Chloroform was added trie-
thylamine (3 mmol).
The solution was stirred and then the benzyl chloride
derivatives, methyl iodide or ethyl iodide were added and
the mixture was heated and stirred under reflux condition.
After completion of the reactions, the precipitated residue
was filtered, recrystallized in ethanol, filtered, washed with
water (2 × 5 mL) and then completely dried in electrical
oven (Scheme 1). All prepared compounds were charac-
terized using FT-IR, 1H NMR, 13C NMR and mass spec-
troscopy (Additional file 1: Table S1).
Acenaphtho[1,2-e]-1,2,4-triazine-9(8H)-thione (3)
Yield 88%, m.p. 148-150°C. 1HNMR (300 MHz, DMSO-
d6) δ: 7.81 (d, 2H, J = 7.5Hz, CH-aromatic), 7.65 (dd, 2H,
J = 7.6, 5.9 Hz, CH-aromatic), 7.46 (d, 2H, J = 8Hz CH-
aromatic), 3.21 (s, 1H, SH); IR (KBr, cm–1): 3245, 3151,
2922, 1689, 1607, 777; 13C-NMR (75 MHz, DMSO-d6) δ:
163, 150, 131, 128, 126, 124, 123; MS: m/z (%) 255 (M+,
51), 213 (100), 180 (75), 152 (49), 139 (44); Anal. Calcd for
C13H7N3S: C, 65.80; H, 2.97; N, 17.71. Found: C, 65.62; H,
2.98; N, 17.58.
9-(benzylthio)-acenaphtho[1,2-e]-1,2,4-triazine (5a)
Yield 94%, m.p. 151-153°C. 1HNMR (300 MHz, DMSO-
d6) δ: 7.78 (d, 2H, J = 7.6Hz, CH-aromatic), 7.61 (dd, 2H,
J = 7.6, 6.6 Hz, CH-aromatic), 7.46 (d, 2H, J = 8.5Hz, CH-
aromatic), 7.05-7.19 (m, 5H, CH-phenyl), 3.26 (s, 2H,
CH2-benzylic); IR (KBr, cm
–1): 3153, 3050, 1694, 1606;
13C-NMR (75 MHz, DMSO-d6) δ: 170.9, 139.7, 142.4,
138.9, 133.5, 128.5, 128.3, 128, 127.8, 127.7, 127.3, 127.2,
126.6, 124.5, 42.2; MS: m/z (%) 327 (M+, 100), 294 (63),
208 (71), 164 (52), 91 (75); Anal. Calcd for C20H13N3S: C,
73.37; H, 4.00; N, 12.83. Found: C, 73.62; H, 3.88; N,
12.58.
Scheme 1 Synthetic rout to acenaphtho[1,2-e]-1,2,4-triazine-9(8H)-thione and 9-(alkylthio)-acenaphtho[1,2-e]-1,2,4-triazines.
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Yield 79%, m.p. 156-158°C. 1HNMR (300 MHz, DMSO-
d6) δ: 8.08 (d, 2H, J = 7.5Hz, CH-phenyl), 7.83 (d, 2H,
J = 7.6Hz, CH-aromatic), 7.75 (dd, 2H, J = 7.3, 6.6 Hz,
CH-aromatic), 7.46 (d, 2H, J = 7.6Hz, CH-phenyl), 7.48
(d, 2H, CH-phenyl), 3.32 (s, 2H, CH2-benzylic); IR (KBr,
cm–1): 3121, 3035, 1670, 1585, 1532, 1486, 937; 13C-NMR
(75 MHz, DMSO-d6) δ: 172.4, 149.8, 145.8, 142.4, 133.5,
131.7, 130.3, 127.6, 127.8, 127.3, 128.9, 128.5, 127.5, 124.1,
44.5; MS: m/z (%) 372 (M+, 12), 255 (48), 213 (100), 180
(87), 152 (62); Anal. Calcd for C20H12N4O2S: C, 64.50; H,
3.25; N, 15.04. Found: C, 64.62; H, 3.18; N, 15.28.
9-(2,4-dichloro-benzylthio)-acenaphtho[1,2-e]-1,2,4-triazine
(5c)
Yield 83%, m.p. 187-188°C. 1HNMR (300 MHz, DMSO-
d6) δ: 7.79 (d, 2H, J = 7.5Hz, CH-aromatic), 7.60 (dd, 2H,
J = 7.5, 6.1 Hz, CH-aromatic), 7.46 (d, 2H, J = 8.3Hz CH-
aromatic), 7.19 (s, 1H, CH-phenyl), 7.09 (d, 1H, J = 7.3Hz,
CH-phenyl), 6.98 (d, 1H, J = 7.3Hz, CH-phenyl), 3.33
(s, 2H, CH2-benzylic); IR (KBr, cm
–1): 3175, 3095,
1656, 1578, 951, 875, 839; 13C-NMR (75 MHz, DMSO-
d6) δ: 171.8, 145.4, 134.5, 134.1, 133.5, 131.4, 130.8,
130.4, 129.2, 128.6, 128.1, 127.9, 127.6, 127.3, 127.1,
125.6, 40.4; MS: m/z (%) 395 (M+, 29), 360 (100), 208
(94), 164 (58); Anal. Calcd for C20H11Cl2N3S: C, 60.62;
H, 2.80; N, 10.60. Found: C, 60.42; H, 2.91; N, 10.73.9-(3,4-dichloro -benzylthio)-acenaphtho[1,2-e]-1,2,4-triazine
(5d)
Yield 60%, m.p. 156-159°C. 1HNMR (300 MHz, DMSO-
d6) δ: 7.80 (d, 2H, J = 7.5Hz, CH-aromatic), 7.52 (dd, 2H,
J = 7.4, 6.2 Hz, CH-aromatic), 7.41 (d, 2H, J = 8.3Hz CH-
aromatic), 7.18 (d, 1H, J = 7.3Hz, CH-phenyl), 7.08 (s, 1H,
CH-phenyl), 6.93 (d, 1H, J = 7.4Hz, CH-phenyl), 3.29
(s, 2H, CH2-benzylic); IR (KBr, cm
–1): 3106, 3019, 1686,
1557, 984, 854; 13C-NMR (75 MHz, DMSO-d6) δ: 170.5,
143.4, 139.2, 133.8, 133.4, 131.8, 130.9, 129.5, 129, 128.6,
128.3, 128.1, 127.6, 127.1, 126.9, 126.5, 38.9; MS: m/z (%)
395 (M+, 46), 362 (13), 255 (53), 213 (100), 180 (85), 152
(54), 86 (83); Anal. Calcd for C20H11Cl2N3S: C, 60.62; H,
2.80; N, 10.60. Found: C, 60.53; H, 2.99; N, 10.44.
9-(4-chloro-benzylthio)-acenaphtho[1,2-e]-1,2,4-triazine (5e)
Yield 84%, m.p. 153-156°C. 1HNMR (300 MHz, DMSO-d6)
δ: 7.89 (d, 2H, J = 7.7Hz, CH-aromatic), 7.58 (dd, 2H, J =
7.5, 6.5 Hz, CH-aromatic), 7.42 (d, 2H, J = 8.6Hz CH-
aromatic), 7.13 (d, 2H, J = 7.5Hz, CH-phenyl); 6.99 (d, 2H,
J = 7.4Hz, CH-phenyl), 3.36 (s, 2H, CH2-benzylic); IR (KBr,
cm–1): 3126, 3058, 1629, 1612, 1597, 1005, 917; 13C-NMR
(75 MHz, DMSO-d6) δ: 169.9, 142.4, 138.7, 137.8, 132.7,
133.5, 129.2, 128.9, 128.3, 128, 127.7, 127.3, 126.1, 125.5,
38.5; MS: m/z (%) 361 (M+, 100), 328 (42), 208 (83), 180
(38), 164 (58), 125 (61); Anal. Calcd for C20H12ClN3S: C,
66.39; H, 3.34; N, 11.61. Found: C, 66.62; H, 3.38; N, 11.40.
Table 1 Cell growth inhibitory activity of synthetic





HL-60 cells MCF-7 cells MOLT-4 cells
5a 48.4 ± 8.7 NAb 30.1 ± 5.6
5b 36.0 ± 5.4 NA 28.0 ± 4.6
5c 51.2 ± 7.6 NA 30.3 ± 8.2
5d NA NA NA
5e 30.1 ± 3.6 NA 33.6 ± 2.9
5f NDc 61.9 ± 20.6 65.5 ± 20.4
5g ND NA NA
Cisplatin 3.0 ± 0.1 23.7 ± 6.8 3.0 ± 0.2
Doxorubicin 0.014 ± 0.002 0.221 ± 0.095 0.017 ± 0.002
aValues represent mean ± S.E.M..
bNA: not active.
cND: not determined.
Mohammadi et al. DARU Journal of Pharmaceutical Sciences 2014, 22:2 Page 4 of 11
http://www.darujps.com/content/22/1/29-(methylthio)-acenaphtho[1,2-e]-1,2,4-triazine (5f)
Yield 31%, 1HNMR (500 MHz, CDCl3): 8.44-8.46 (m, 2H,
CH-aromatic), 8.24 (m, 1H, CH-aromatic), 8.14 (d, 1H,
J = 8.25 Hz, CH-aromatic), 7.86-7.90 (m, 2H, CH-aromatic),
2.84 (s, 3H, -CH3); IR (KBr, cm
-1): 3150, 2923, 1615, 1416
and 1382; Anal. Calcd for C14H9N3S: C, 66.91; H, 3.61; N,
16.72. Found: C, 66.82; H, 3.68; N, 16.59.
9-(ethylthio)-acenaphtho[1,2-e]-1,2,4-triazine (5g)
Yield 30%, 1HNMR (500 MHz, DMSO-d6): 8.38-8.44
(m, 3H, CH-aromatic), 8.29 (d, 1H, J = 8.1 Hz, CH-
aromatic), 7.91-7.96 (m, 2H, CH-aromatic), 3.33 (q, 2H,
CH2-CH3), 1.44-1.47 (t, 3H, J = 7.2 Hz, CH2-CH3); IR
(KBr, cm -1): 3148, 2944, 1617, 1420 and 1381; Anal.
Calcd for C15H11N3S: C, 67.90; H, 4.18; N, 15.84. Found:
C, 68.06; H, 4.28; N, 15.73.
Cytotoxicity assay
RPMI 1640, fetal bovine serum (FBS), trypsin and phos-
phate buffered saline (PBS) were purchased from Biosera
(Ringmer, UK). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) was obtained from Sigma
(Saint Louis, MO, USA) and penicillin/streptomycin
was purchased from Invitrogen (San Diego, CA, USA).
Doxorubicin and dimethyl sulphoxide were obtained
from EBEWE Pharma (Unterach, Austria) and Merck
(Darmstadt, Germany), respectively.
HL-60 (human promyelocytic leukemia), MCF-7 (human
breast adenocarcinoma) and MOLT-4 (human acute lym-
phoblastic leukemia) cells were obtained from the National
Cell Bank of Iran, Pasteur Institute, Tehran, Iran. All cell
lines were maintained in RPMI 1640 supplemented with
10% FBS, and 100 units/mL penicillin-G and 100 μg/mL
streptomycin. Cells were grown in monolayer cultures.
Cell viability following exposure to synthetic com-
pounds was evaluated by using the MTT reduction
assay. HL-60, MCF7, and MOLT-4 cells were plated in
96-well microplates at a density of 5 × 104 cells⁄ mL
(100 μl per well). Positive control wells contained cis-
platin and doxorubicin and blank wells contained only
growth medium for background correction. After over-
night incubation at 37°C, half of the growth medium
was removed and 50 μL of medium supplemented with
different concentrations of synthetic compounds dis-
solved in DMSO were added in quadruplicate. Max-
imum concentration of DMSO in the wells was 0.5%
(The solution of 0.5% DMSO was also tested as a cyto-
toxicity control). Cells were further incubated for 72 h.
At the end of the incubation time, the medium was re-
moved and MTT was added to each well at a final con-
centration of 0.5 mg⁄mL and plates were incubated for
another 4 h at 37°C. Then formazan crystals were solubi-
lized in 200 μl DMSO. The optical density was measured
at 570 nm with background correction at 655 nm usinga Bio-Rad microplate reader (Model 680). The percent-
age of viability compared to control wells was calcu-
lated for each concentration of the compound and
IC50 values were calculated with the software CurveEx-
pert version 1.34 for Windows. Each experiment was
repeated 3–4 times. Data are represented as mean ±
S.E.M.
Molecular docking study
The ligand-flexible docking studies were performed
using the widely distributed molecular docking software,
AutoDock 4.2 [26]. Lamarckian Genetic Algorithm of
the AutoDock 4.2 program was used to perform the
flexible-ligand docking studies [27]. All the x-ray crystal-
lographic holo structures of Bcl-2 were retrieved from
the Brookhaven protein data bank (http://www.rcsb.org/).
The protein structure was subjected to optimization
step in order to minimize the crystallographic induced
bond clashes using steepest descent method. All the
preprocessing steps for receptor and ligand files were
done by Auto-Dock Tools 1.5.4 (ADT) [28]. For the
preparation of protein, Kollman united atom charges
and polar hydrogen’s were added to the receptor and
crystallographic waters were removed. For docked li-
gands, Gasteiger charge was assigned, non-polar hydro-
gens were merged into the related carbon atoms of the
receptor and torsions degrees of freedom were also allo-
cated by ADT program.
Lamarckian genetic algorithm (LGA) was used to
simulate the binding affinity and binding mode of ace-
naphtho derivatives in the active site of Bcl-2. 100 inde-
pendent genetic algorithm (GA) runs were considered
for each ligand under study. For Lamarckian GA; 27000
maximum generations; a gene mutation rate of 0.02; and
Table 2 Top ranked AutoDock scores based on the binding free energies (ΔG) of acenaphtho structures docked into





Amino acids in non-bonded contacts
Amino acid Distance (Å)




Asp10, Gly46, Glu50Ser49 2.50
Lys17 1.73
5c −8.09 Arg12 1.96 Glu13, Met16, Ala32, Val36, Glu38, Asn39, Thr41
5d −8.22 Arg12 2.20 Glu13, Met16, Ala32, Asp35, Val36, Glu38, Asn39, Thr41
5e −7.73 Arg12 2.16 Glu13, Met16, Ala32, Asp35, Val36, Glu38, Asn39, Thr41
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the protein were calculated using AutoGrid (part of the
AutoDock package). The size of grid was set in a way to
include not only the active site but also considerable
portions of the surrounding surface. For this purpose, a
grid of 60 × 60 × 60 points in x, y, and z directions was
built centered on the center of mass of the catalytic site
of Bcl-2 with a spacing of 0.375 Å. Cluster analysis was
performed on the docked results using an Root mean
square deviation (RMSD) tolerance of 2 Å.
Ligand-receptor interactions were all detected on the
basis of docking results using LIGPLOT [29]. Molecular
images were produced using VMD program [30].
Results and discussion
Chemistry
Some new acenaphtho derivatives were obtained by
condensation of acenaphtylene-9,10-quinone and thio-
semicarbazide followed by reaction with different benzyl
chloride derivatives under mild conditions in chloro-
form solution (Scheme 1). The isolated compounds
were then characterized by elemental analyses, FT-IR,
MS and NMR spectroscopy. The applied synthetic
method afforded all the 9-(alkylthio)-acenaphtho[1,2-e]-
1,2,4-triazines in high yields and short reaction times
except for 9-(methylthio) and 9-(ethylthio) derivatives
that were produced in lower yields (Additional file 1:
Table S1).Table 3 Top ranked AutoDock scores based on the binding fr





Amino acid Distance (Å
5a −6.78 Ser49 2.18
5b −9.13 Asp10 1.87
5c −8.11 Ala32 2.36
5d −7.74 -
5e −7.84 -Cytotoxicity assay
The in vitro cytotoxic activities for prepared acenaphtho
derivatives are shown in Table 1.
All the compounds under study exhibited medium cyto-
toxic activity on the evaluated cancerous cell lines except for
9-(methylthio) (5f) and 9-(ethylthio) (5 g) derivatives. Com-
pound 5 g was inactive in MCF-7 and MOLT-4 cells. Com-
pound 5b showed higher cytotoxicity in MOLT-4 cells. In
HL-60 cells, compound 5e exhibited superior cytotoxic ac-
tivity. The order of cytotoxic effects in HL-60 and MOLT-4
cell lines could be shown as 5e > 5b > 5a > 5c > 5d and 5b >
5a > 5c > 5e > 5f > 5d = 5 g. Variations of cytotoxic results
were less pronounced for MOLT-4 cell lines. Moreover, all
of the tested compounds were inactive on MCF-7 cells ex-
cept for 5f which exhibited an IC50 value of 61.9 μM.
With the exception of compound 5e, a common
trend, might be deduced that the presence of electron
withdrawing/hydrogen acceptor nitro group on the
phenyl ring of 9-(alkylthio)-acenaphtho[1,2-e]-1,2,4-
triazines afforded higher cytotoxic effects while halo-
genated compounds showed lower in vitro potencies. It
was also revealed that acenaphtho derivatives bearing
aralkyl substituents on their sulfur atom (5a-e) might
exhibit better cytotoxicity profiles than acenaphtho de-
rivatives bearing alkyl substituents (5f and 5 g). Further
structure activity relationship developments is under
investigation via preparing more diverse sets of these
derivatives.ee energies (ΔG) of acenaphtho structures docked into
mino acids of Bcl-2
Amino acids in non-bonded contacts
)
Thr7, Pro44, Gly46, Glu48, Glu50
Thr7, Gly8, Tyr9, Glu13, Thr41, Glu42, Ala43, Pro44, Gly46, Ser49
Glu13, Met16, His20, Trp30, Asp31, Gly33, Val36
Glu13, Met16, His20, Glu29, Trp30, Ala32
Glu13, Met16, His20, Glu29, Trp30, Ala32
Figure 1 H-bond interactions of compound 5b in the active site of Bcl-2 isoforms a) PDB ID: 1G5M and b) PDB ID: 1GJH.
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We decided to gain some information on binding modes
of tested compounds on the Bcl-2 active site via molecu-
lar docking. Previous reports proposed that despite the
similarity in the structures of two Bcl-2 isoforms, they
behave differently in binding to the pro-apoptotic mem-
bers of the Bcl-2 family [31]. For this purpose we de-
cided to conduct our modeling studies on the structures
of the two isoforms of Bcl-2 protein (isoforms 1: 1G5M
and isoform 2: 1GJH).
Due to the lower cytotoxic activities of 9-(methylthio)
and 9-(ethylthio) derivatives and also considering our main
focus on 9-(Aralkylthio)-acenaphtho[1,2-e]-1,2,4-triazines
rather than 9-(alkylthio)-acenaphtho[1,2-e]-1,2,4-triazines,
all modeling studies were performed on 9-(benzylthio)
derivatives.
Validation of molecular docking
A performance of a typical docking protocol can be
checked via testing its ability in predicting predominant
binding mode of a cognate (co-crystallographic) ligand.
This procedure is performed via extracting the structure
of a cognate ligand and re-docking it into its receptor
(self-docking). RMSD of the Cartesian coordinates of the
atoms of the ligand in the docked and crystallographic
conformations will be the criterion of the docking valid-
ation (RMSD ≤ 2 Å).
Various PDB derived Bcl-2 structures were subjected to
docking validation procedure. PDB structures were chosen
on the basis of crystallographic resolutions. Regarding
RMSD values and also conformation population in the
top-ranked cluster of AutoDock output file, 1G5M and
1GJH were selected as the most appropriate crystallo-
graphic structure for further modeling studies.
Docking simulation of acenaphtho derivatives
Considering the well obtained in vitro results, it was
thought worthy to perform molecular docking studies,
hence considering both in silico and in vitro results.Owing to the potential apoptosis-inducing activity of ace-
naphtho scaffolds via the Bcl-2 protein [17], we decided to
model the binding interactions of assayed 9-(alkylthio)-
acenaphtho[1,2-e]-1,2,4-triazines in the active site of Bcl-2
via docking simulation. For this purpose, 9-(alkylthio)-ace-
naphtho[1,2-e]-1,2,4-triazines were all docked into the
active site of selected receptors i.e. various isoforms of
Bcl-2 (1G5M and 1GJH) which differed in two amino
acids [31].
Docking results with isoforms 1 (PDB code: 1G5M) and
2 (PDB code: 1GJH) are summarized in Tables 2 and 3,
respectively. Top ranked binding energies (kcal/mol) in
AutoDock dlg output files were considered as the best
docking result in each case. It should be noted that all top
ranked clusters were supported by high conformation
populations. This observation could be expected since
literature evidence implied that docking studies with
compounds bearing less active torsions can significantly
promote the docking success rates due to the limited con-
formational degrees of freedom [32].
In silico results revealed that synthesized molecules
showed relatively good binding energies toward Bcl-2
active site ranging from −7.03 to −9.29 kcal/mol in iso-
form1 (1G5M) and −6.78 to −9.13 kcal/mol in isoform 2
(1GJH). Estimated binding energies were in the order of
5b > 5d > 5c > 5e > 5a in the active site of isoform 1 and
5b > 5c > 5d > 5e > 5a in the active site of isoform 2. The
trends may also highlight slight conformational differ-
ences for two Bcl-2 isoforms [31].
Molecular docking study revealed that 9-(alkylthio)-
acenaphtho[1,2-e]-1,2,4-triazine derivatives (5a-e) may
inhibit Bcl-2 protein via H-bond and hydrophobic inter-
actions (Tables 2 and 3). Compound 5b exhibited the
best docking score (Tables 2 and 3) while being most po-
tent in human MOLT-4 cells (Table 1). It seemed that
the presence of para-nitro substituent on phenyl ring of
5b might be responsible for additional H-bonds with the
active site of the receptor. This H-bond acceptor site
would potentially support one key H-bond interactions
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isoform 2 through oxygen atom of a nitro substituent
(Figure 1). The profile of interaction in 5b (Figure 1) fur-
ther announced us that para nitro substituent in 9-(4-ni-
tro-alkylthio)-acenaphtho[1,2-e]-1,2,4-triazine (5b) might
have some directional effect on the active site oriented
conformation of the ligand. This rationale could be
shown in Figure 2 in which different orientation of
acenaphtho cycle in 5b compared to other compounds is
obviously detectable. This new orientation would re-
locate a triazine ring in a position to make H-bondFigure 2 H-bond interactions between acenaphtho derivatives (5a, 5cinteractions with Ser49 and Glu48 via polar hydrogen of
N15 atom (Figures 1 and 3). From another aspect of
view, docking simulation could be applied to find the
binding mode and mechanism of less active derivatives.
To add more, it seemed that H-bond connections con-
tributed more significantly in complex stabilization in
the case of 5b and Bcl-2 isoform 1 (1G5M) rather than
isoform 2 (1GJH). Compounds 5a, 5c, 5d and 5e all par-
ticipated in key H-bonds with nitrogen atoms of a tria-
zine ring (Figure 2). We found that Arg12 interacted via
its guanine side chain (NH1; Figure 2) with nitrogen, 5d and 5e) and active site residues in isoform 1 of Bcl-2.
Figure 3 Different active site oriented conformations for docked acenaphtho derivatives (5a, 5b, 5c, 5d and 5e) in the active site of
Bcl-2 isoform 1.
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Figure 2).
Docking of commonly used neoplastic drugs i.e. Geftinib,
Cisplatin, 5-FU, Gemcitabine and Vinorelbine into the
active site of Bcl-2 (isoform 1; 15GM) has been reported
elsewhere [6]. It was revealed that Asp10, Glu13, Lys17,
Glu42 and Ser49 contributed to H-bond formation with
the docked drugs [6]. Same residues were found to be key
H-bond/non-bonded participants for inhibitor recognition
in our study. Docking results showed that Glu13 contrib-
uted to non-bonded contacts with 5a, 5b, 5c and 5d
(Table 1) while Asp10 participated in non-bonded con-
tacts with 5b. Moreover; H-bond network in the case
of Cisplatin (Asp10, Lys17 and Ser49) was very similar
to that of 5b (Lys17, Glu48 and Ser49). The residue
atoms involved in the binding pattern were the same
for cisplatin and 5b in the case of Lys17 (quaternary
NH of side chain; Figure 1) while for Ser49, cisplatin
interacted with hydroxyl group of the Ser49 side chain
but compound 5b made hydrogen bond via Ser49 back-
bone NH (Figure 1). Lys17 has also been reported to be
involved in efficient H-bonds with Geftinib, Gemcita-
bine and Vinorelbine while stabilizing H-bonds were
detected in the case of Glu13 for Gemcitabine and
Vinorelbine [6].
Literature data revealed the effect of position of sub-
stituent(s) on phenyl moiety in comparison to our results
[33]. It has been discussed that considering substituentFigure 4 Compounds 5b (left) and 5d (right) in the active site of Bcl-2groups being attached to the para or meta-position,
the hydrophobic pocket of Bcl-2 exhibited varied tol-
erability. This further identified the size of the hy-
drophobic pocket of Bcl-2 to be limited. Meta or
para-halogen atoms on phenyl ring induce different
conformations leading to decreased interactions with
hydrophobic pocket of Bcl-2 (compounds 5d and 5f )
(Figure 4).
Molecular docking on human anti-apoptotic Bcl-2 fur-
ther supported the biological data. Regarding the obtained
results, compound 5b could serve as an appropriate start-
ing point for designing new chemical entities as potent
Bcl-2 inhibitors.
Binding efficiency indices
Another criterion which has recently absorbed much
attention in ligand-receptor interaction studies is the lig-
and efficiency (LE) parameter. Nowadays LE indices are
regarded as undeniable tools in modern drug discovery
projects [34]. The model of analyzing ligand binding in
terms of the free energy per heavy atom (heavy atom
count; HAC) was first introduced by Andrews [35]. Con-
cept of the binding energy per atom or binding efficiency
of a ligand could be a useful parameter in the selection
of lead compounds, considering the real potency of a
compound and hence might consider optimized frag-
ments [36]. Generally speaking, molecules achieving a
desirable potency with fewer HACs are by definition.
Table 4 Experimental/theoretical binding/ligand efficiency indices for 9-(benzylthio)-acenaphtho[1,2-e]-1,2,4-triazine derivatives (Bcl-2, isoforms 1 & 2,
PDB IDs: 1G5M & 1GJH)





























5a 1G5M 48.4 4.32 0.179 0.208 13.20 15.77 5a 1G5M 30.1 4.52 0.188 0.208 13.83 15.77
5b 1G5M 36.0 4.44 0.114 0.134 11.95 14.36 5b 1G5M 28.0 4.55 0.190 0.134 12.24 14.36
5c 1G5M 51.2 4.29 0.165 0.228 10.86 15.01 5c 1G5M 30.3 4.52 0.188 0.228 11.44 15.01
5d 1G5M - - - 0.218 - 15.26 5d 1G5M - - - 0.218 - 15.26
5e 1G5M 30.1 4.52 0.170 0.219 12.52 15.69 5e 1G5M 33.6 4.47 0.186 0.219 12.39 15.69
5a 1GJH 48.4 4.31 0.179 0.214 13.20 15.24 5a 1GJH 30.1 4.52 0.188 0.214 13.83 15.24
5b 1GJH 36.0 4.44 0.114 0.137 11.95 14.05 5b 1GJH 28.0 4.55 0.190 0.137 12.24 14.05
5c 1GJH 51.2 4.29 0.165 0.228 10.86 15.04 5c 1GJH 30.3 4.52 0.188 0.228 11.44 15.04
5d 1GJH - - - 0.232 - 14.36 5d 1GJH - - - 0.232 - 14.36
5e 1GJH 30.1 4.52 0.170 0.237 12.52 15.18 5e 1GJH 33.6 4.47 0.186 0.237 12.39 15.18
aLE values are defined in the range of 0–1 [34].
bEstimated LEs were calculated according to equation (2).
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the equations (1) or (2):
LE ¼ ‐ ΔGb
HAC
ð1Þ
LE ¼ ‐ pKi; pKd;or pIC50
HAC
ð2Þ
Regarding the ligand efficiencies, it was postulated that
molecular weights are prior to the HACs in considering
the contribution of heteroatoms from different rows of
the periodic table [37]. Thus a modified efficiency value
was suggested as binding efficiency index (BEI). The im-
portance of BEI can be emphasized regarding an in-
crease in molecular weight at the clinical candidate step,
which is regarded as an undeniable paradox with a com-
mon trend towards lower MWs and better pharmacoki-
netic profiles in marketable drugs [38]. BEI could be
easily estimated from equation (3):
BEI ¼ ‐ pKi; or pIC50
MW kDað Þ ð3Þ
Accordingly, assayed acenaphtho derivatives were re-
evaluated on the basis of their experimental and theoret-
ical BEI/LE values (Table 4).
Regarding the summarized data in Table 4, following
rationales might be pointed out:
– In our calculations, estimated LEs in terms of
pKi values (equation 2) produced results more
compatible to the experimental LEs (cellular
assays) when compared to the LEs in terms of ΔGb
values (equation 1; the related data are not shown
in the Table).
– Compound 5b is the top ranked bioactive molecule
in docking results and also MOLT-4 based cellular
assay. But this compound achieved relatively lower
scores in terms of experimental/theoretical efficiency
indices. The observed paradox demonstrated that
larger bioactive compounds may require special
attention in their design toward efficiency indices [25].
– Efficient bioactive molecules may be better
categorized considering estimated BEIs rather than
LEs. In some cases, especially for molecules bearing
larger atoms, incorporating molecular weights rather
than number of heavy atoms in the calculation of
efficiency indices produced less biased results.
– The application of theoretical ligand/binding
efficiency indices in the cell –based cytotoxicity
protocols should be considered with care due to the
multi-target nature of the cytotoxic agents. For
example, compound 5d which is the structural isomer
of compound 5c, was inactive in MTTassays.Conclusion
Various studies have demonstrated that chemical
structures bearing sulfur atom(s) may possibly induce
apoptosis [39,40]. On the basis of results from this
study, corresponding 9-(benzylthio) acenaphtho[1,2-
e]-1,2,4-triazines might be regarded as valuable cyto-
toxic polycyclic heterocycles and potential candidates
for additional molecular modifications with the aim of
developing potent cytotoxic agents. Experimental and
modeling studies confirmed the previous reports on
acenaphtho derivatives and moreover; the docking re-
sults agreed well with the observed in silico data for
commonly used anticancer drugs. Despite the close-
ness of docking scores, relatively different binding pro-
files for acenaphtho derivatives might confirm the
previous results on conformational difference between
two Bcl-2 isoforms. Concept of binding efficiency as a
common and well–approached tool in modern drug
discovery strategies was reviewed in our study. Con-
firming previous reports, it was demonstrated that bio-
active molecular design on the basis of potency alone
or binding efficiency values might be considered as dif-
ferent strategies leading to dissimilar results in lead/
drug development campaigns. However several litera-
ture reports demonstrated that lead/drug discovery
projects on the basis of binding efficiency indices
would afford bioactive compounds with better phar-
macokinetic outcomes. Extended cytotoxicity assays on
diverse sets of acenaphtho-based scaffolds with the aim
of establishing more rational structure activity
relationships are under investigation.
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